Smith & Nephew plc Stock Rating Reaffirmed by Deutsche Bank
's stock had its "buy" rating reiterated by equities researchers at Deutsche Bank in a research report issued on Friday.
Smith & Nephew plc Given "Outperform" Rating at Sanford C. Bernstein
's stock had its "outperform" rating restated by equities researchers at Sanford C. Bernstein in a research report issued on Wednesday.
Smith & Nephew plc Given "Neutral" Rating at Goldman Sachs
's stock had its "neutral" rating restated by equities research analysts at Goldman Sachs in a research note issued to investors on Tuesday.
Smith & Nephew temporarily ceases commercial distribution of RENASYS in the U.S.
Smith & Nephew temporarily ceases commercial distribution of RENASYS in the U.S. Smith & Nephew announces that it has temporarily ceased commercial distribution of the RENASYS Negative Pressure Wound Therapy product line in the United States.
S & N ceases U.S. distribution of Ranasys
Smith & Nephew temporarily ceases distribution of the Renasys Negative Pressure Wound Therapy product line in the U.S. The stoppage is per instructions from the FDA that Renasys needs new 510 regulatory clearance because of design enhancements that have been made to the product.
Does Covidien merger mean Smith & Nephew is off Medtronic's list?
Yesterday's announcement that Medtronic Inc. was merging with Covidien will most likely be the largest, but possibly not the last, acquisition the company makes this year.
European Stocks Decline for a Second Day on Iraq Conflict
European stocks dropped for a second day as Sunni insurgents made further territorial gains in Iraq , while investors awaited a report on U.S. industrial production.
Smith & Nephew gets more attractive
Being small in a world of giants has long cast replacement-joint maker Smith & Nephew PLC in the role of takeover target, but a new European tax crackdown could make it more so.